Publication date: Nov 01, 2024
Protracted COVID-19 is increasingly recognised in immunocompromised patients, particularly those with haematological malignancies. Here, we present the case of a patient with protracted COVID-19 and an underlying B-cell malignancy. Standard COVID-19 treatment with remdesivir and steroids proved ineffective in this patient as she continued to have evolving ground-glass opacities on imaging. A multidisciplinary involvement altered treatment to include a combination of antivirals nirmatrelvir/ritonavir (Paxlovid) and remdesivir, a monoclonal antibody and immunoglobulins leading to a clinical cure. This report highlights the need for a more tailored approach in this patient sub-group than the rest of the population.
Concepts | Keywords |
---|---|
Covid | covid-19 |
Haematological | cycle threshold |
Immunocompromised | ground-glass opacity |
Ineffective | hematologic malignancy |
immunocompromised |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | MESH | Pneumonitis |
disease | MESH | Follicular Lymphoma |
disease | MESH | immunocompromised patients |
disease | MESH | malignancies |
disease | IDO | cell |
drug | DRUGBANK | Ritonavir |
disease | MESH | hematologic malignancy |